Ann: Chairman's Address and CEO presentaiton to AGM, page-2

First page
INVION LIMITED AGM: CHAIR’S ADDRESS & CEO PRESENTATION

Brisbane, Australia and Delaware, United States, 18 November 2015: Invion Limited (ASX: IVX) is pleased to provide the Chair’s Address and CEO presentation to the 2015 Annual General Meeting of Shareholders being held today at 2.00pm (AEST) at the offices of McCullough Robertson Lawyers, Level 11, 66 Eagle Street Brisbane.

Address to Shareholders by Mr Brett Heading, Chair of the Board of Directors

As shareholders will know from recent announcements and other communications, 2015 has seen your company deliver against major strategic and clinical development milestones.

Managing Director and CEO, Dr Greg Collier, will shortly speak in detail about the status of the company’s pipeline, however I am pleased to stand before you today and report, that with three drug assets across four development programs, Invion has achieved major milestones this year including:

1. confirming pre-IND status for inhaled INV102 (nadolol) as a potential therapy for asthma, COPD & cystic fibrosis and the commencement of toxicology studies for that strategy;
   
   
2. the completion of the phase 2 clinical trial of INV103 (ala-Cpn10) in lupus patients;
   
   
3. the selection of formulation and a device for inhaled INV104 (zafirlukast) and the commencement of manufacturing for toxicology and clinical supplies for that program;
   
   
4. and most significantly, the completion of the 155-patient Phase 2 smoking cessation trial which reported positive safety and efficacy data in October.
   

In summary, the Phase 2 smoking cessation data demonstrated that treated patients receiving INV102 (nadolol) were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked than untreated patients.

We believe this is highly positive data for the company and validates management’s clinical development strategy. It also places the company in a good position for the achievement of another major milestone – which is an End of Phase 2 Meeting with the US FDA on this program.